Helicobacter pylori infection. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
Conditions
Interventions
Intervention 1: Intervention group: 5-day treatment group regimen: Amoxicillin: 1000 mg twice daily, Levofloxacin 500 mg once daily (Tavanex®, abidi pharma), Pantoprazole 40 mg twice daily (abidi Phar
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: All individuals aged 18 to 60 with a histologically confirmed Helicobacter pylori infection The patient's consent to participate in the study
Exclusion criteria
Exclusion criteria: Prior treatment for H. pylori eradication Severe and chronic medical conditions Pregnant women History of NSAID, antibiotic, or PPI use within the last 30 days Prior stomach surgery Severe kidney dysfunction [serum creatinine >2 mg/dL] Severe liver dysfunction Known hypersensitivity to levofloxacin, amoxicillin, or pantoprazole Gastric cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter Pylori infection eradication. Timepoint: Five weeks after completing treatment (two weeks after stopping pantoprazole). Method of measurement: Helicobacter pylori stool antigen test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effect- Constipation. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Diarrhea. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Nausea. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Vomiting. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Abdominal pain. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Heartburn. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Metallic taste. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Flatulence. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Dizziness. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Low appetite. Timepoint: Before starting the study, 5 days after starting treatment, and at the end of treatment. Method of measurement: Ask the patient in person or by phone.;Adverse effect- Headache. Timepoint: Before starting the study, 5 days after starting treatment, a | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmin Vahedi
Babol University of Medical Sciences
Outcome results
None listed